Withdrawal from fixed-dose injection of methamphetamine decreases cerebral levels of 3-methoxy-4-hydroxyphenylglycol and induces the expression of anxiety-related behavior in mice

Neurochemical Research

Volumn 35, Issue 5, 2010, Pages 749-760

  Kitanaka, Nobue ^a   Kitanaka, Junichi ^a   Tatsuta, Tomohiro ^a   Tanaka, Koh Ichi ^a   Watabe, Kaname ^b   Nishiyama, Nobuyoshi ^a   Morita, Yoshio ^a   Takemura, Motohiko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Technical Department   (Japan)

Author keywords

Amphetamine withdrawal; Animal model; Anxiety related behavior; Methamphetamine; Norepinephrine

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; METHAMPHETAMINE;

ABSTINENCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DYSPHORIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT GAIN; WITHDRAWAL SYNDROME;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; MALE; METHAMPHETAMINE; METHOXYHYDROXYPHENYLGLYCOL; MICE; MICE, INBRED ICR; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA; MUS; RATTUS;

EID: 77953292995     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-010-0132-4     Document Type: Article

References (35)

1. Lago JA, Kosten TR (1994) Stimulant withdrawal. Addiction 89:1477-1481
2. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52-58
3. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226
4. Booij L, Van der Does AJW, Riedel WJ (2003) Monoamine depletion in psychiatric and healthy population: review. Mol Psychiatry 8:951-973
5. Stahl SM, Grady MM, Moret C, Briley M (2005) SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrum 10:732-747
6. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (2005) The nature, time course and severity of methamphetamine withdrawal. Addiction 100:1320-1329
7. Kalechstein AD, Newton TF, Longshore D, Anglin MD, van Gorp WG, Gawin FH (2000) Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 12:480-484
8. Kantak KM (2003) Vaccines against drugs of abuse: A viable treatment option? Drugs 63:341-352
9. Dopheide JA (2006) Recognizing and treating depression in children and adolescents. Am J Health Syst Pharm 63:233-243
10. Kokkinidis L, Zacharko RM, Anisman H (1986) Amphetamine withdrawal: a behavioral evaluation. Life Sci 38:1617-1623
11. Murphy CA, Fend M, Russig H, Feldon J (2001) Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage schedule of amphetamine. Behav Neurosci 6:1247-1256
12. Russig H, Pezze M-A, Nanz-Bahr NI, Pryce CR, Feldon J, Murphy CA (2003) Amphetamine withdrawal does not produce a depressive-like state in rats as measured by three behavioral tests. Behav Pharmacol 14:1-18
13. Kitanaka J, Kitanaka N, Takemura M (2008) Neurochemical consequences of dysphoric state during amphetamine withdrawal: a review. Neurochem Res 33:204-219
14. Post RM (1980) Intermittent versus continuous stimulation: effect of time interval on the development of sensitization. Life Sci 26:1275-1282
15. Eison MS, Eison AS, Iversen SD (1983) Two routes of continuous amphetamine administration induce different behavioral and neurochemical effects in the rat. Neurosci Lett 39:313-319
16. Robinson TE, Camp DE (1987) Long-lasting effects of escalating doses of d-amphetamine on brain monoamines, amphetamineinduced stereotyped behavior and spontaneous nocturnal locomotion. Pharmacol Biochem Behav 26:821-827
17. Lin D, Koob GF, Markou A (2000) Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacol Biochem Behav 65:407-417
18. Cryan JF, Hoyer D, Markou A (2003) Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54:49-58
19. Russig H, Murphy CA, Feldon J (2005) Behavioural consequences of withdrawal from three different administration schedules of amphetamine. Behav Brain Res 165:26-35
20. Peleg-Raibstein D, Sydekum E, Feldon J (2006) Differential effects on prepulse inhibition of withdrawal from two different repeated administration schedules of amphetamine. Int J Neuropsychopharmacol 9:737-749 (Pubitemid 46122773)
21. Kuczenski R, Segal DS, Cho AK, Melega W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15:1308-1317
22. Segal DS, Kuczenski R (1997) An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 17:2551-2566
23. Kitanaka J, Kitanaka N, Tatsuta T, Morita Y, Takemura M (2007) Blockade of brain histamine metabolism alters methamphetamine- induced expression pattern of stereotypy in mice via histamine H1 receptors. Neuroscience 147:765-777
24. Kitanaka N, Kitanaka J, Tatsuta T, Watabe K, Morita Y, Takemura M (2006) Methamphetamine reward in mice as assessed by conditioned place preference test with Supermex- sensors: effect of subchronic clorgyline pretreatment. Neurochem Res 31:805-813
25. Kitanaka N, Kitanaka J, Takemura M (2003) Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration. Eur J Pharmacol 474:63-70
26. Schildkraut JJ, Watson R, Draskoczy PR, Hartmann E (1971) Amphetamine withdrawal: depression and M.H.P.G. secretion. Lancet 2:485-486
27. Watson R, Hartmann E, Schildkraut JJ (1972) Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion. Am J Psychiatry 129:263-269
28. Hoffman EJ, Mathew SJ (2008) Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med 75:248-262
29. Short PH, Shuster L (1976) Changes in brain norepinephrine associated with sensitization to d-amphetamine. Psychopharmacology (Berl) 48:59-67
30. Maas JW, Landis DH (1968) In vivo studies of the metabolism of norepinephrine in the central nervous system. J Pharmacol Exp Ther 163:147-162
31. Schanberg SM, Schildkraut JJ, Breese GR, Kopin IJ (1968) Metabolism of normetanephrine-H3 in rat brain: identification of conjugated 3-methoxy-4-hydrophenylglycol as the major metabolite. Biochem Pharmacol 17:247-254
32. Kitanaka N, Kitanaka J, Takemura M (2005) Repeated clorgyline treatment inhibits methamphetamine-induced behavioral sensitization in mice. Neurochem Res 30:445-451
33. Bueno CH, Zangrossi H Jr, Viana Mde B (2007) GABA/benzodiazepine receptors in the ventromedial hypothalamic nucleus regulate both anxiety and panic-related defensive responses in the elevated T-maze. Brain Res Bull 74:134-141
34. Schallek W, SchlosserW(1979) Neuropharmacology of sedatives and anxiolytics. Mod Probl Pharmacopsychiatry 14:157-173
35. Smith RJ, Aston-Jones G (2008) Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 213:43-61